$10.27
+0.02 (+0.20%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ECOR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
18 interventional · 1 observational · 15 with posted results
Held by 4 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 7.6 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Non-invasive Vagus Nerve Stimulation for the Prevention of MigrainesNCT03716505Safety and effectiveness of gammaCore Sapphire as a treatment for the prevention of a migraine during the double-blind period measured by Incidence of Unexpected Adverse Events.Randomized · Quadruple-masked · Prevention | Not applicable | Completed | Device: gammaCore Sapphire active, gammaCore Sapphire Sham | Migraine Disorders | 231 | 2020-09-09actual | 2020-09-11 |
| A Randomized, Multicenter, Study for the prEvention and Acute Treatment of Migraine (REAL)NCT03787238Reduction in number of migraine days during the last four weeks in the twelve-week randomized period compared with the four-week run-in periodRandomized · Open-label · Prevention | Not applicable | Withdrawnsponsor's stated reason: Company decision | Device: non-invasive vagus nerve stimulation | Migraine | 0 | 2020-09-01 | 2019-06-14 |
| A Randomized, Sham-controlled Study of gammaCore ® (nVNS) for Prevention of Episodic MigraineNCT02378844results2019-08-19Change in the Number of Migraine DaysRandomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: gammaCore®-R, gammaCore®-R Sham | Migraine | 477 | 2018-02-01actual | 2019-08-19 |
| RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine AttacksNCT02686034results2019-08-02Number of Participants With Treatment Response - No PainRandomized · Quadruple-masked · Treatment | Not applicable | Completed | Device: gammaCore-S, gammaCore-S Sham | Migraine | 285 | Dec 2016actual | 2019-08-02 |
| A Randomized, Single Centre, Double-blind, Parallel, Sham-controlled Pilot Study Using gammaCore®-GNCT02388269results2018-02-06Symptom Changes in Subjects With Functional Gastrointestinal Disorder (Functional Dyspepsia and Irritable Bowel Syndrome)Randomized · Triple-masked · Prevention | Not applicable | Completed | Device: gammaCore®-G | Dyspepsia, Irritable Bowel Syndrome | 91 | May 2015actual | 2018-03-07 |
| A Randomized Multicentre Study for the Acute Relief of Episodic and Chronic Cluster Headache.NCT01958125results2019-02-26Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the TreatmentRandomized · Triple-masked · Treatment | Not applicable | Completed | Device: gammaCore | Cluster Headache | 102 | Oct 2014actual | 2019-02-26 |
| Neurostimulation to the Vagus Nerve for the Reduction in Frequency of Seizures Associated With EpilepsyNCT01910129results2019-04-23Frequency of SeizuresRandomized · Double-masked · Prevention | Not applicable | Terminatedsponsor's stated reason: Slow enrollment | Device: gammaCore | Seizure | 13 | Jul 2014actual | 2019-04-23 |
| Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster HeadacheNCT01792817results2018-05-17Number of Participants With Repsonse to TreatmentRandomized · Triple-masked · Treatment | Not applicable | Completed | Device: GammaCore, Sham GammaCore device | Cluster Headache | 150 | Jun 2014actual | 2019-12-17 |
| Non-Invasive Neurostimulation for the Prevention of Chronic MigraineNCT01667250results2018-06-20Safety - Number of Participants With Adverse EventsRandomized · Double-masked · Prevention | Not applicable | Completed | Device: GammaCore Active Device, GammaCore Sham Device | Chronic Migraine | 59 | May 2014actual | 2018-06-20 |
| Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of CareNCT01701245results2016-04-25A Change in the Frequency of Cluster Headache Attacks Per WeekRandomized · Open-label · Treatment | Phase 2 | Completed | Device: GammaCore | Chronic Cluster Headache | 97 | Mar 2014actual | 2016-04-25 |
| Vagus Nerve Stimulation for Management of Bronchoconstriction in Patients Hospitalized With COPD ExacerbationsNCT01612793results2019-02-28observationalChange in the Length of Stay in the Hospital | — | Terminated | Device: AlphaCore Device | Chronic Obstructive Pulmonary Disease | 4 | Apr 2013actual | 2019-02-28 |
| Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic TreatmentNCT01679314results2016-05-09Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Scores (Quality of Life and Symptoms) Changes Within a Treatment Period and Comparison Between the Two GroupsRandomized · Single-masked · Treatment | Not applicable | Completed | Device: AlphaCore device | Chronic Obstructive Pulmonary Disease | 54 | Jan 2013actual | 2016-05-09 |
| Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore Device for the Relief of EIBNCT01923272Randomized · Double-masked · Treatment | Not applicable | Withdrawnsponsor's stated reason: Similar study being conducted, Sponsor decided to not duplicate study | Device: AlphaCore Device, AlphaCore | Asthma | 0 | Oct 2012actual | 2013-08-15 |
| Non-Invasive Neurostimulation For the Relief of Symptoms Associated With MigraineNCT01532830results2018-05-11Safety - Number of Participants With Adverse EffectsOpen-label · Treatment | Not applicable | Completed | Device: n-VNS | Migraine | 30 | Jul 2012actual | 2018-07-10 |
| Noninvasive Neurostimulation of the Vagus Nerve for the Relief of Acute Bronchoconstriction Due to AsthmaNCT01385306results2018-10-10Number of Participants With Adverse EventsOpen-label · Supportive care | Not applicable | Terminatedsponsor's stated reason: Slow enrollment | Device: AlphaCore System | Asthma | 6 | May 2012actual | 2018-11-09 |
| Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore DeviceNCT01532817results2018-04-09Safety- Number of Participants With Adverse EventsOpen-label · Treatment | Not applicable | Completed | Device: AlphaCore | Asthma | 30 | May 2012actual | 2018-04-09 |
| Non-invasive Neurostimulation for the Relief of MigraineNCT03410628results2018-07-26Safety - Number of Participants With Adverse EventsOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Company decision | Device: gammaCore | Migraine | 21 | Aug 2011actual | 2018-07-26 |
| Neurostimulation for the Relief of Acute BronchoconstrictionNCT00762931results2018-05-15Safety- Number of Participants With Adverse EventsOpen-label · Treatment | Not applicable | Completed | Device: Resolve Stimulator and Proximity Lead | Asthma | 25 | Sep 2010actual | 2018-05-15 |
| Neurostimulation for the Treatment of Post-Operative IleusNCT00854074To validate the design of ElectroCore Resolution Motility System™ , to safely place a stimulation electrode in the epidural space of the spine in a post-operative subject, and to evaluate the subject's ability to tolerate stimulation for up to 48 hoursRandomized · Open-label · Treatment | Not applicable | Withdrawnsponsor's stated reason: Withdrawn: study halted prematurely, prior to enrollment of first participant | Device: ElectroCore RMS-1100 Resolution Motility System™ | Ileus | 0 | Dec 2009 | 2018-02-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19